Catalog No.
DHE16601
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
FLK-1, Kinase insert domain receptor, VEGFR2, Fetal liver kinase 1, CD309, Vascular endothelial growth factor receptor 2, Protein-tyrosine kinase receptor flk-1, FLK1, VEGFR-2, KDR
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P35968
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
1121B, IMC-1121B, LY3009806, CAS: 947687-13-0
Clone ID
Ramucirumab
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial, PMID: 25240821
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial, PMID: 31591063
Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer, PMID: 31452409
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial, PMID: 24933332
Ramucirumab: A Review in Hepatocellular Carcinoma, PMID: 32034692
Ramucirumab, PMID: 27340327
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial, PMID: 30665869
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study, PMID: 25877855
Ramucirumab, PMID: 31643324
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial, PMID: 24094768
Ramucirumab and its use in the treatment of hepatocellular carcinoma, PMID: 30644314
Ramucirumab, PMID: 29999742
The safety of ramucirumab for the treatment of colorectal cancer, PMID: 30073902
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial, PMID: 31753727
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial, PMID: 26095784
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ), PMID: 32827847
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY, PMID: 32954593
Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence, PMID: 32547208
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial, PMID: 30718072
Ramucirumab: the long and winding road toward being an option for mCRC treatment, PMID: 30917706
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial, PMID: 28916371
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF), PMID: 29853658
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial, PMID: 31301962
Ramucirumab: Boon or bane, PMID: 27025409
[Ramucirumab - a new anticancer agent], PMID: 27690622
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 + T cells in the tumor microenvironment, PMID: 30314524
Molecular therapies and precision medicine for hepatocellular carcinoma, PMID: 30061739
Gastric cancer, PMID: 27156933
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer, PMID: 29353164
Nephrotic syndrome associated with ramucirumab therapy: A single-center case series and literature review, PMID: 31277139
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial, PMID: 27765757
Ramucirumab for gastric cancer, PMID: 25431958
Ramucirumab: first global approval, PMID: 24916147
Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer, PMID: 32719002
Ramucirumab: A Review in Advanced Gastric Cancer, PMID: 26341713
Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?, PMID: 30879152
The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer, PMID: 32021422
Ramucirumab in the treatment of non-small cell lung cancer, PMID: 28395526
Ramucirumab: A vascular endothelial growth factor receptor-2 inhibitor with activity in several malignancies, PMID: 27217518
Ramucirumab: successfully targeting angiogenesis in gastric cancer, PMID: 25281695
Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein, PMID: 30464931
Osimertinib plus Ramucirumab: The Best of Both Worlds?, PMID: 33334907
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy, PMID: 27565938
Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors, PMID: 26887374
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study, PMID: 30339194
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2, PMID: 32279446
Ramucirumab for the treatment of advanced or metastatic non-small cell lung cancer, PMID: 27737562
Ramucirumab: targeting angiogenesis in the treatment of gastric cancer, PMID: 25496333
Current status of ramucirumab in gastroesophageal adenocarcinoma, PMID: 28436242
Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma, PMID: 26557893
For research use only. Not for human or drug use.
